0L49.L - SCYNEXIS, Inc.
| Previous close | 2.3900 |
| Open | 0.0000 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 0.0000 - 0.0000 |
| 52-week range | |
| Volume | |
| Avg. volume | 5,912 |
| Market cap | N/A |
| Beta (5Y monthly) | 2.16 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Scynexis (SCYX) Reports Q1 Loss, Misses Revenue Estimates
Scynexis (SCYX) delivered earnings and revenue surprises of 10.71% and 24.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- Simply Wall St.
SCYNEXIS, Inc.'s (NASDAQ:SCYX) largest shareholders are individual investors with 51% ownership, institutions own 48%
Key Insights The considerable ownership by individual investors in SCYNEXIS indicates that they collectively have a...
- Simply Wall St.
We Might See A Profit From SCYNEXIS, Inc. (NASDAQ:SCYX) Soon
SCYNEXIS, Inc. ( NASDAQ:SCYX ) is possibly approaching a major achievement in its business, so we would like to shine...
- Zacks
Scynexis (SCYX) Inks Antifungal Drug Deal With GSK
Scynexis (SCYX) enters an exclusive license agreement with GSK to commercialize Brexafemme (ibrexafungerp), an antifungal tablet. GSK will also continue to develop ibrexafungerp for treating invasive candidiasis.
- Simply Wall St.
SCYNEXIS, Inc. (NASDAQ:SCYX) insiders are still down US$113k after purchasing last year, recent gain helped regain some losses
Some of the losses seen by insiders who purchased US$236k worth of SCYNEXIS, Inc. ( NASDAQ:SCYX ) shares over the past...
- Simply Wall St.
SCYNEXIS (NASDAQ:SCYX) shareholders are up 14% this past week, but still in the red over the last five years
It's nice to see the SCYNEXIS, Inc. ( NASDAQ:SCYX ) share price up 14% in a week. But that doesn't change the fact that...
- Simply Wall St.
SCYNEXIS Third Quarter 2022 Earnings: Misses Expectations
SCYNEXIS ( NASDAQ:SCYX ) Third Quarter 2022 Results Key Financial Results Net loss: US$29.6m (loss widened by US$29.0m...
- Zacks
Scynexis (SCYX) Reports Q3 Loss, Misses Revenue Estimates
Scynexis (SCYX) delivered earnings and revenue surprises of -21.57% and 17.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Earnings Preview: Scynexis (SCYX) Q3 Earnings Expected to Decline
Scynexis (SCYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
Great news for SCYNEXIS, Inc. (NASDAQ:SCYX): Insiders acquired stock in large numbers last year
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...
- Zacks
Scynexis (SCYX) Reports Q2 Loss, Tops Revenue Estimates
Scynexis (SCYX) delivered earnings and revenue surprises of 7.02% and 12.12%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- Simply Wall St.
The past five years for SCYNEXIS (NASDAQ:SCYX) investors has not been profitable
Some stocks are best avoided. It hits us in the gut when we see fellow investors suffer a loss. Spare a thought for...
